Clene Inc. (CLNN)
Official siteCONSUMER DEFENSIVE • PACKAGED FOODS • NASDAQ
Market Cap: $56.45M
Last updated: Nov 17, 2026 at 11:05 AM ET
Clene Inc. (CLNN) Stock Forecast
Analysts expect Clene (CLNN) to earn -$2.62 per share in the fiscal year ending Dec 31, 2026, on revenue of $250600. Of 5 analysts, 5 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 1.80, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 20.0% |
| Buy | 4 | 80.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 9185.7%.
- Fiscal year ending Dec 31, 2026
- -$2.62
- EPS consensus, revenue $250600
- Fiscal year ending Dec 31, 2027
- -$2.44
- EPS consensus, revenue $23.27M
- Next report
- Mar 10, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.62 | -$2.78 to -$2.46 | 2 | $250600 | $105000 to $400000 | 5 |
| Dec 31, 2027 | -$2.44 | -$3.46 to -$1.42 | 2 | $23.27M | $200000 to $62.40M | 5 |
Quarterly Estimates
The EPS consensus falls from -$0.45 for the quarter ending Dec 31, 2026 to -$0.66 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.45 | -$0.52 to -$0.37 | 7 | $85680 | $15680 to $178500 | 7 |
| Mar 31, 2027 | -$0.66 | -$0.74 to -$0.58 | 2 | $58000 | $16000 to $100000 | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 5 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 2 |
| Fiscal year ending Dec 31, 2027 | 0 | 2 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.41.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.62 | -$1.41 | -$1.41 | -$1.41 | -$1.41 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.44 | -$1.79 | -$1.79 | -$1.79 | -$1.43 | N/A |
| Quarter ending Mar 31, 2027 | -$0.66 | -$0.39 | -$0.39 | -$0.39 | -$0.39 | N/A |
Frequently Asked Questions About CLNN
What is the CLNN stock forecast?
Consensus analyst estimates put Clene's EPS at -$2.62 for the fiscal year ending Dec 31, 2026, on revenue of $250600. The consensus rating from 5 analysts is Buy.
How do analysts rate CLNN stock?
Of 5 analysts covering Clene, 1 rates it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CLNN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.62, with estimates from -$2.78 to -$2.46 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.44, with estimates from -$3.46 to -$1.42 from 2 analysts.
What revenue do analysts expect from Clene next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $250600, with estimates from $105000 to $400000. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $23.27M, with estimates from $200000 to $62.40M.
How many analysts cover CLNN?
5 analysts rate Clene stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CLNN pages: Overview, Earnings, Forecast, Financials, Competitors